which contribute to their role in normal and diseased states will be outlined and evidence for their participation in lung disease discussed.
The matrix metalloproteases (MMPs) Nine members of the MMP family have been identified. All are produced and secreted in a latent, proenzyme form. Gelatins, collagens IV, V, VII, X, XII, fibronectin, MMP-2 (EC 3.4.24.24) elastin, PG-core protein 72 Many of these cytokines also enhance production of TIMP-1 ( Evidence from wound healing systems indicate that regulated MMP expression and production by stromal cells is required for tissue remodelling7 -a process which presumably takes place in the lungs of ARDS survivors. It is suggested that the excessive fibrosis observed in the lungs of non-survivors is a result of an unregulated repair process. 74 Whether the outcome is repair or fibrosis, MMPs produced by alveolar fibroblasts, macrophages, epithelial and endothelial cells are likely to have a significant role. To date, however, the participation of these MMPs in ARDS has received little attention. A recent study which demonstrates increased interstitial collagenase expression in the lungs of rats following hyperoxic injury (a model with similarities to ARDS) suggests that this may prove a fruitful area for future investigation.75
MMPs AND INTERSTITIAL FIBROSIS
As indicated above, fibrosis -the common end stage of several interstitial lung diseases -is thought to reflect an aberrant wound healing response. The injury which triggers the response varies from neutrophil mediated tissue damage (cryptogenic fibrosing alveolitis) to granuloma formation in response to known (extrinsic allergic alveolitis) and unknown (sarcoidosis) antigens, direct tissue damage (asbestos, silica), and injury resulting from abnormal immune responses (collagen vascular diseases). Whatever the initial cause, a common feature of all the above mentioned diseases is she development of a chronic inflammation which causes continual and repeated injury to the alveoli over a prolonged period. This chronic injury may, as suggested for acute injury in ARDS, destroy the extracellular matrix scaffold of the alveoli to such an extent that the structural template required for normal repair is destroyed. The continued low grade inflammation also ensures that cells within the injured alveoli are constantly exposed to inflammatory cytokines which modulate their expression of a range of cell products involved in fibrosis including extracellular matrix proteins, MMPs, and TIMP (table 2) .
MMPs can participate in the fibrotic process at two stages: (1) at the injury stage by degrading basement membrane and extracellular matrix constituents; and (2) at the "attempted repair" stage where modulation of the production or action of MMPs may contribute to the abnormal tissue remodelling observed. (It must be remembered, however, that both injury and attempted repair are likely to occur side by side in the fibrotic lung. ) Collagenase activity has been detected in BAL fluids from patients with cryptogenic fibrosing alveolitis, rheumatoid interstitial lung disease, sarcoidosis, and asbestosis.637679 In all these cases the collagenase present displays characteristics of the neutrophil derived enzyme. In both rheumatoid interstitial lung disease and sarcoidosis, collagenase levels in BAL fluid were higher in patients with established fibrosis than in those without evidence of fibrotic scarring.637778 In some patients with sarcoidosis the presence of collagenase in BAL fluid preceded pulmonary deterioration. 80 These studies suggest that neutrophil collagenase may play a part in tissue injury in fibrosis.
Information on the participation of interstitial collagenase in fibrosis comes largely from studies carried out by Selman and colleagues. A unifying hypothesis on the involvement of MMPs in fibrosis encompassing all the above observations would involve (1) collagenase (and probably gelatinase B) released from inflammatory polymorphonuclear leucocytes contributing to initial tissue injury, and (2) a decrease in interstitial collagenase expression by fibroblasts and/or other stromal cells contributing to subsequent aberrant repair and accumulation of collagen. In this regard, Selman and colleagues have noted that lung fibroblast lines from patients with cryptogenic fibrosing alveolitis constitutively produce less interstitial collagenase than lines from normal lung. 83 We have also observed decreased collagenase production in a fibroblast line derived from BAL cells recovered from a patient with systemic lupus erythematosus (unpublished observations). In vitro studies indicate that several cytokines known to be present in inflammatory situations, including TGF,B, IL-4 and IFNy, are capable of reducing expression of interstitial collagenase by fibroblasts and monocytes/macrophages (table 2). As previously indicated, TGFI also increases collagen production and production of TIMP-1. Studies which indicate that TGFI3 promotes gelatinase expression in fibroblasts3940 raise the intriguing possibility that, while "driving" fibroblasts to produce and deposit components of the interstitial matrix, this cytokine also enhances their capability to degrade basement membrane. Thus, under the influence of this cytokine the action of fibroblasts would ideally "fit" that required for producing fibrosis in situations where the extent of injury and/or continued inflammation prevented healing.
While most studies have concentrated on the role of interstitial and neutrophil collagenases in interstitial fibrosis, the potential involvement of other MMPs cannot be ignored. We have detected gelatinase B in BAL fluids from patients with cryptogenic fibrosing alveolitis, extrinsic allergic alveolitis and sarcoidosis (unpublished results), and the transient expression and activity of gelatinase A by alveolar macrophages from patients with sarcoidosis has been observed by Garbisa et 
Future directions
Research in recent years has highlighted the involvement of common cytokines and growth factors in a range of seemingly diverse processes including cell migration, proliferation and transformation; destructive inflammatory disorders; resorptive processes; fibrosis and tumorigenesis. The involvement of common mediators suggests similarities in underlying cellular mechanisms. In vivo, all of these processes require or are accompanied by change and reorganisation of the surrounding extracellular matrix. The most likely mechanism by which cytokines and growth factors exert their modulating effects on the extracellular matrix is via the induction or repression of MMPs and their inhibitors.2 Thus, the potential application of therapies targeted at MMP regulation is considerable. As outlined in this review, recent advances in our understanding of these regulatory mechanisms now make it possible to design and examine such therapies.
